Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.60 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480343 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL4480365 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL4495195 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL6560264 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL6560280 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL6560281 | 1.00 | DPP4 (0.60) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL10793019 | 0.88 | ACE (0.51) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL7340816 | 0.88 | ACE (0.51) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL10793023 | 0.88 | ACE (0.51) | DPP4ACEMAPTCYP3A4TSHR | |
| SCHEMBL10915073 | 0.87 | ACE (0.50) | DPP4ACEMAPTCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| US-7326785-B2 | Pyrrolidine derivatives as factor XA inhibitors | GLAXO GROUP LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7186717-B2 | Pyrrolidine derivatives as Factor Xa inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7084139-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor Xa | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1395553-B1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2005-02-16 | — | — | EP | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | DPP4 2567/4885ACE 407/4885MAPT 4836/4885 |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | TFPI, F2, SERPINC1 | DPP4 916/4885ACE 324/4885MAPT 4509/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | DPP4 1780/4885ACE 408/4885MAPT 4534/4885 |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | DPP4 916/4885ACE 324/4885MAPT 4509/4885 |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | DPP4 916/4885ACE 324/4885MAPT 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.